Top 20 of Asthma

Article title # Publications/# Citations

Interleukin-13: central mediator of allergic asthma.

1998: DDDonaldson; CLKarp; JLuyimbazi; TYNeben; BSchofield; MWills-Karp; XXu;

457

The B7 family revisited.

2005: GJFreeman; RJGreenwald; AHSharpe;

406

Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

1992: JBarkans; AMBentley; CCorrigan; SRDurham; QHamid; ABKay; DSRobinson; ATsicopoulos; SYing;

403

Asthma and wheezing in the first six years of life. The Group Health Medical Associates.

1995: MHalonen; CJHolberg; FDMartinez; WJMorgan; LMTaussig; ALWright;

371

Requirement for IL-13 independently of IL-4 in experimental asthma.

1998: FBrombacher; DBCorry; DDDonaldson; GGrünig; RMLocksley; MMohrs; DMRennick; DSheppard; ... RVenkayya; AEWakil; MWarnock;

338

Epidemiology Standardization Project (American Thoracic Society).

1978: BGFerris;

310

Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.

2000: HDKleber; DCLewis; ATMcLellan; CPO'Brien;

308

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

1992: CMBaveystock; PWJones; PLittlejohns; FHQuirk;

295

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009.

2009: 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team; SRBenoit; AMBramley; CBBridges; SChen; RChugh; MDeutscher; JKDruckenmiller; ... JSDuchin; LFinelli; AEFiore; AMFry; SJain; SJasuja; LKamimoto; SLett; JLouie; SJOlsen; KARitger; AMSchmitz; SSoliva; DESugerman; DSwerdlow; TMUyeki; JDWalker; EVWells;

294

Improving primary care for patients with chronic illness: the chronic care model, Part 2.

2002: TBodenheimer; KGrumbach; EHWagner;

293

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007.

2007: National Asthma Education and Prevention Program;

291

Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma.

2007: GRAbecasis; ABufe; WOCookson; MDepner; ALDixon; MFarrall; TFrischer; IGGut; ... SHeath; AHeinzmann; TIllig; MKabesch; GMLathrop; LLiang; MFMoffatt; ERietschel; BSimma; DStrachan; CVogelberg; Avon Berg; Evon Mutius; SKWeiland; SAWillis-Owen; KCWong;

284

The global burden of asthma: executive summary of the GINA Dissemination Committee report.

2004: Global Initiative for Asthma (GINA) Program; RBeasley; DFabian; SHolt; MMasoli;

271

Evidence based physical activity for school-age youth.

2005: CJBlimkie; SRDaniels; RKDishman; BGutin; ACHergenroeder; RMMalina; AMust; PANixon; ... JMPivarnik; TRowland; WBStrong; STrost; FTrudeau;

268

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.

1999: QChen; JAElias; GPGeba; RJHomer; JWang; ZWang; YZhang; ZZhu;

263

Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee.

1998:

261

International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods.

1995: HRAnderson; MIAsher; RBeasley; JCrane; UKeil; FMartínez; EAMitchell; NPearce; BSibbald; AWStewart;

254

Asthma.

2001: WWBusse; RFLemanske;

248

Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.

2006: ISAAC Phase Three Study Group; MIAsher; BBjörkstén; CKLai; SMontefort; DPStrachan; SKWeiland; HWilliams;

240

Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen.

2002: KBottomly; SCEisenbarth; CAHerrick; JWHuleatt; DAPiggott; IVisintin;

238